Lisa M. Holle - Search Results

Year	Number of Results
2013	2
2014	4
2015	3
2016	5
2017	3
2018	1
2019	4
2020	4
2021	4
2023	2
2024	1
2025	2
2026	0

1

2022-2023 Drug Updates in Solid Tumors.

Holle LM. Holle LM. J Adv Pract Oncol. 2024 Apr;15(3):170-176. doi: 10.6004/jadpro.2024.15.3.3. Epub 2024 Apr 1. J Adv Pract Oncol. 2024. PMID: 39297067 Free PMC article.

2

The Expanding Role of the Oncology Pharmacist.

Holle LM, Segal EM, Jeffers KD. Holle LM, et al. Pharmacy (Basel). 2020 Jul 25;8(3):130. doi: 10.3390/pharmacy8030130. Pharmacy (Basel). 2020. PMID: 32722357 Free PMC article.

3

Safe Administration of Intracerebral Spinal Fluid Chemotherapy: Time for Guidelines.

Clement JM, Holle LM. Clement JM, et al. Among authors: holle lm. J Oncol Pract. 2017 Nov;13(11):713-718. doi: 10.1200/JOP.2017.022038. Epub 2017 Aug 29. J Oncol Pract. 2017. PMID: 28850310 No abstract available.

4

Updates in the Treatment of Non-Metastatic Castrate-Resistant Prostate Cancer: The Benefit of Second-Generation Androgen Receptor Antagonists.

Hadfield MJ, Lyall V, Holle LM, Dennison M. Hadfield MJ, et al. Among authors: holle lm. Ann Pharmacother. 2023 Nov;57(11):1302-1311. doi: 10.1177/10600280231155441. Epub 2023 Feb 24. Ann Pharmacother. 2023. PMID: 36840339 Review.

5

Lutetium Lu 177 vipivotide tetraxetan: A literature review.

Morrison G, Holle LM. Morrison G, et al. Among authors: holle lm. J Oncol Pharm Pract. 2025 Nov 11:10781552251392083. doi: 10.1177/10781552251392083. Online ahead of print. J Oncol Pharm Pract. 2025. PMID: 41217772 Review.

6

Demonstrating the value of the oncology pharmacist within the healthcare team.

Segal EM, Bates J, Fleszar SL, Holle LM, Kennerly-Shah J, Rockey M, Jeffers KD. Segal EM, et al. Among authors: holle lm. J Oncol Pharm Pract. 2019 Dec;25(8):1945-1967. doi: 10.1177/1078155219859424. Epub 2019 Jul 9. J Oncol Pharm Pract. 2019. PMID: 31288634

7

Pharmacist intervention in colorectal cancer screening initiative.

Holle LM, Levine J, Buckley T, White CM, White C, Hadfield MJ. Holle LM, et al. J Am Pharm Assoc (2003). 2020 Jul-Aug;60(4):e109-e116. doi: 10.1016/j.japh.2020.02.014. Epub 2020 Mar 18. J Am Pharm Assoc (2003). 2020. PMID: 32197754

8

Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.

Pherwani N, Ghayad JM, Holle LM, Karpiuk EL. Pherwani N, et al. Among authors: holle lm. Am J Health Syst Pharm. 2015 Apr 15;72(8):619-31. doi: 10.2146/ajhp140194. Am J Health Syst Pharm. 2015. PMID: 25825185 Review.

9

Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection.

Jensen CM, Holle LM. Jensen CM, et al. Among authors: holle lm. Pharmacotherapy. 2016 May;36(5):562-74. doi: 10.1002/phar.1748. Epub 2016 May 12. Pharmacotherapy. 2016. PMID: 27027412 Review.

10

Late onset imatinib-induced Stevens-Johnson syndrome.

Bois E, Holle LM, Farooq U. Bois E, et al. Among authors: holle lm. J Oncol Pharm Pract. 2014 Dec;20(6):476-8. doi: 10.1177/1078155213518226. Epub 2014 Jan 7. J Oncol Pharm Pract. 2014. PMID: 24399835

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year